
































for	 the	majority	of	BMP	activity	 in	plasma.	BMP9	and	BMP10	bind	preferentially	 to	 the	high	
affinity	 type	 I	 receptor	 activin	 receptor-like	 kinase	 1	 (ALK1)	 on	 vascular	 endothelial	 cells.	
Recently,	a	number	of	reports	have	highlighted	the	important	roles	of	BMP9	in	cardiovascular	
disease,	 particularly	 pulmonary	 arterial	 hypertension	 (PAH).	 In	 vivo,	 BMP9	 activity	 and	
specificity	 are	 determined	 by	 tightly	 regulated	 protein-protein	 recognition	 with	 cognate	
receptors	and	a	co-receptor,	and	may	also	be	influenced	by	other	proteins	present	on	endothelial	
cell	 surface	 (such	 as	 low	 affinity	 receptors)	 and	 in	 circulation	 (such	 as	 TGFb	 family	 ligands	
competing	for	the	same	receptors).	In	this	review,	we	summarise	recent	findings	on	the	role	and	
therapeutic	potential	of	BMP9	in	cardiovascular	disease,	and	review	the	current	understanding	













human	 pulmonary	 artery	 endothelial	 cells;	 ENG:	 endoglin;	 HHT:	 hereditary	 haemorrhagic	
telangiectasia;	 AVM:	 arteriovenous	malformation;	 TAC:	 transverse	 aortic	 constriction;	 AMD:	
age-related	macular	degeneration;	ALK1-Fc:	ALK1	extracellular	domain-Fc	fusion	protein;	GFD:	
growth	 factor	 domain;	 ActRIIa/b:	 Activin	 type	 II	 receptor	 a/b;	 ActA:	 activin	 A;	 Pro-BMP9:	








endothelial	 cells,	 inhibiting	 endothelial	 cell	 apoptosis,	 migration,	 proliferation	 and	
angiogenesis(2-4).	Dysregulated	BMP	signalling	causes	endothelial	dysfunction	which	plays	a	










ALK1/BMPRII	complex,	 is	exclusively	expressed	 in	 the	right	atrium	in	 the	adult(8).	Bmp9	 -/-	
mice	 are	 grossly	 normal	 apart	 from	 defects	 in	 lymphatic	 vessels	 and	 delayed	 closure	 of	 the	
ductus	arteriosus(9-12),	whereas	Bmp10	-/-	mice	are	embryonic	lethal(10).	Although	there	have	
been	no	reports	of	differences	between	BMP9	and	BMP10	signalling	in	endothelial	cells	in	vitro,	
studies	 from	 knockout	 mice	 suggest	 that	 BMP9	 may	 play	 a	 more	 prominent	 role	 in	 the	







for	 the	human	autosomal	genetic	disorder	hereditary	haemorrhagic	 telangiectasia	 (HHT)(14,	
15).	 HHT	 is	 characterised	 by	 the	 presence	 of	 multiple	 arteriovenous	malformations	 (AVM),	






aortic	 constriction	 (TAC),	Bmp9	knockout	mice	 displayed	 a	more	 severe	 fibrotic	 phenotype,	












comes	 from	 a	 report	 that	 mouse	 pups	 receiving	 neutralising	 antibodies	 against	 BMP9	 and	
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the	development	of	PAH.	Genetic	mutations	 in	BMPR2,	ALK1	and	ENG	have	all	been	 found	 in	
patients	with	idiopathic	or	heritable	forms	of	PAH(27-30).	Recently,	a	large-scale	whole-genome	
sequencing	 study	 in	 1038	 PAH	 index	 cases	 not	 only	 confirmed	 the	 mutations	 in	 the	 BMP9	
receptors,	but	also	identified	heterozygous	pathogenic	mutations	in	BMP9	itself	(31).	Structural	
and	 functional	 analyses	 suggested	 that	 these	mutations	 lead	 to	 reduced	 cellular	 secretion	of	









cirrhosis	 patients	 with	 advanced	 liver	 disease	 exhibit	 very	 low	 plasma	 levels	 of	 BMP9.	 The	
lowest	 levels	 are	 found	 in	 cirrhosis	 patients	 who	 develop	 PAH	 (known	 as	 portopulmonary	
hypertension)(35).	In	fact,	low	plasma	BMP9	levels	were	a	good	predictor	for	the	presence	of	
PAH	in	cirrhosis	patients.	The	same	investigators	showed	inhibition	of	plasma	BMP9	and	BMP10	





protects	 against	 experimental	 pulmonary	 hypertension(36),	 observations	 that	 superficially	
appear	 to	 be	 at	 odds	 with	 our	 earlier	 report(7).	 Tu	 et	 al.	 proposed	 that	 BMP9	 confers	 a	
vasoconstrictive	effect	by	inducing	factors	such	as	endothelin-1	and	suppressing	vasodilation	








human	 genetic	 evidence	 that	 loss-of-function	 in	 the	 BMP9	 signalling	 axis	 promotes	 the	
development	of	PAH(5).	 
In	summary,	human	genetics	studies	support	a	central	role	of	compromised	BMP9	signalling	in	
PAH	and	HHT,	 and	preclinical	 studies	 suggest	 the	beneficial	 effects	 of	 recombinant	BMP9	 in	
rodent	models	of	PAH,	cardiac	fibrosis	and	AMD.	Therefore,	a	thorough	understanding	of	the	







over	 30	 ligands,	 including	 BMPs,	 growth	 and	 differentiation	 factors,	 activins,	 and	 TGFβ	
ligands(38).		The	TGFβ	family	is	highly	conserved	in	eukaryotes,	controlling	myriad	important	
processes	such	as	embryonic	stem	cell	self-renewal,	differentiation,	morphogenesis,	and	tissue	














and	 receptors	 share	 the	 same	 three-dimensional	 structural	 fold	 and	 signalling	 complex	






BMP-receptor	 interactions	was	 largely	 obtained	 using	 only	 BMP	 GFDs.	 	 In	 vivo,	 prodomain-
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bound	 BMP9	 (pro-BMP9)	 is	 likely	 to	 simultaneously	 encounter	 a	 number	 of	 extracellular	
proteins	that	might	bind	itself	or	its	receptors.	Figure	1B	summarises	such	extracellular	BMP9	




Molecular	mechanisms	 of	BMP	 signalling	 have	 been	 studied	 at	 the	 structural	 level	 for	many	
years.	Early	efforts	were	focused	on	the	bone-forming	BMPs,	such	as	BMP2	and	BMP7,	which	
were	investigated	clinically	as	a	therapy	to	promote	bone	reunion	following	fracture.	Although	






human	 GFD	 (4YCG,	 4YCI)(44),	 one	 crystal	 structure	 for	 the	 ternary	 signalling	 complex	 of	
ALK1:BMP9:ActRIIb	 (4FAO)(25),	 and	 one	 crystal	 structure	 for	 BMP9	 bound	 to	 the	 orphan	
domain	of	the	co-receptor	ENG	(5HZW)(24).	This	has	greatly	facilitated	the	understanding	of	
BMP9	regulation	and	signalling	at	the	molecular	level.	Equipped	with	such	structural	knowledge,	
we	can	now	begin	 to	pinpoint	 the	specific	protein-protein	 interactions	 that	 could	potentially	





At	physiologically	 relevant	 concentrations,	BMP9	signalling	 in	 endothelial	 cells	 is	 exclusively	
mediated	by	the	high	affinity	receptor	ALK1(3).	At	higher	BMP9	concentrations	and	after	co-
stimulating	with	lipopolysaccharides	or	tumour	necrosis	factor-a,	ALK2	can	also	be	activated(49,	




has	 also	 been	 shown	 to	 promote	 ovarian	 cancer	 cell	 proliferation(52).	 The	 direct	 binding	
affinities	 between	BMP9	and	 seven	TGFb	 family	 type	 I	 receptors	 have	been	measured	using	





a5	 helix	 from	 the	 prodomain	 occupies	 the	 type	 I	 receptor-binding	 site	 in	 the	 crystal	





The	 type	 II	 site	 on	 BMP9	 interacts	 with	 several	 partners,	 including	 the	 prodomain,	 type	 II	
receptors	and	the	co-receptor	ENG	(Figure	1B).	Interestingly,	these	interactions	share	significant	
overlap	of	binding	epitopes	on	BMP9,	suggesting	they	cannot	bind	BMP9	simultaneously,	which	




analysis	 of	 the	 reported	 affinities	 (Table	 2)	 for	 these	 interactions	 does	 not	 prove	 that	 such	
signalling	complex	formation	is	solely	dependent	on	the	relative	affinities.	In	addition,	although	
the	affinities	between	ALK1-Fc	with	both	BMP9	GFD	and	pro-BMP9	are	of	similar	high	affinity	





listed	 have	 used	 solid-surface	 based	 binding	 assays,	 which	 do	 not	 always	 reflect	 binding	 in	













down	 either	 ACTR2a	 or	 BMPR2	 in	 these	 cells	 with	 specific	 small	 interfering	 RNA	 reduced	
osteogenic	activity	of	BMP9(56).	Because	mutations	in	BMPR2	but	not	ACTR2a/b	are	found	in	
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BMP	 signalling	 is	 also	 influenced	 by	 proteins	 that	 function	 as	 ligand	 traps,	 such	 as	 noggin,	
however,	BMP9	and	BMP10	are	 insensitive	 to	noggin	 inhibition(2,	57).	 It	 is	unclear	whether	
BMP9	 and	 BMP10	 are	 influenced	 by	 other	 endogenous	 ligand	 traps.	 One	 candidate	 is	
crossveinless	2	 (CV2),	a	 chordin	 family	BMP	 ligand	 trap(58).	 It	was	shown	 that	BMP9/ALK1	
signalling	in	endothelial	cells	can	induce	the	expression	of	CV2	and	that	CV2	can	bind	BMP9	in	
pull-down	 and	 immunoprecipitation	 assays.	 In	 the	 same	 report,	 the	 authors	 provide	 data	













been	 found	 in	 the	 circulation(60,	 61).	BMP9	 could	potentially	 share	BMPRII	with	BMP4	and	










although	 it	 is	 helpful	 to	use	model	 cell	 lines	 to	dissect	 receptor	 and	 ligand	 interactions,	 it	 is	
essential	to	validate	the	regulation	of	BMP	signalling	in	the	primary,	physiologically	relevant	cell	








there	 are	 a	 number	 of	 intracellular	 and	 extracellular	BMP	 signalling	modifiers,	 such	 as	BMP	
signalling	inhibitors	SMAD6,	SMURF,	ligand	trap	NOGGIN	and	BAMBI	etc.	Such	a	feedback	loop	
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seems	 to	 be	 a	 common	 theme	 in	 TGFb	 family	 signalling,	 emphasizing	 the	 importance	 of	
maintaining	BMP	 signalling	 at	 optimum	 levels.	 2)	The	 organism	may	 regulate	BMP9	protein	
stability	and	mRNA	synthesis;	 for	example,	we	have	shown	previously	 that	circulating	BMP9	




on	 vascular	 endothelium	 and	 possibly	 also	 endocardium.	 4)	 It	 was	 recently	 reported	 the	
presence	of	BMP9	and	BMP10	heterodimer	 in	plasma,	which	should	signal	through	the	same	
type	 I	 receptor	 ALK1	 in	 endothelial	 cells	 as	 BMP9	 therefore	 could	 add	 another	 layer	 of	
complexity	to	the	regulation	of	BMP9	signalling(62).	5)	Many	other	cellular	signalling	pathways	





• The importance of the field 
The	circulating	BMPs,	BMP9	and	BMP10,	are	important	players	in	an	emerging	axis	of	vascular	
endothelial	 protection.	 Human	 genetics	 studies	 confirm	 that	 loss	 of	 signalling	 via	 this	 axis	
promotes	 the	 development	 of	 PAH	 or	 HHT.	 Augmentation	 of	 circulating	 BMP9	 produced	
beneficial	effects	in	pre-clinical	models	of	PAH,	cardiac	fibrosis	and	AMD,	and	reversed	the	loss	
of	functional	endothelial	BMP9	signalling	in	rodent	models	of	PAH.	A	better	understanding	of	




• Summary of the current thinking 
Human	genetic	data	strongly	support	a	compromised	endothelial	BMP9/ALK1/BMPRII	axis	as	
causative	 for	 PAH.	 In	 addition,	 loss-of-function	 in	 ENG	 or	 ALK1	 can	 cause	 HHT.	 Current	
knowledge	from	structural	biology,	protein-protein	interactions	and	signalling	assays	in	human	
primary	endothelial	cells	have	provided	a	wealth	of	information	on	the	mechanisms	by	which	
BMP9	and	BMP10	signal.	The	 specificity	 and	high	binding	affinity	 for	ALK1	make	BMP9	and	
BMP10	particularly	potent	ligands	on	endothelial	cells.	
 
• Future directions 
Future	 research	 should	 aim	at	 understanding	 the	paradox	why	 loss-of-function	 in	 the	BMP9	
signalling	 axis	 can	 on	 the	 one	 hand	 cause	 HHT	 and	 yet	 also	 promote	 PAH.	 The	 type	 II	 site	






























































































































































































































































































































Kd or EC50 
(nM)* 






20°C, ELISA binding assay, EC50. Mi et al.(44)  
37°C, Biacore. Kienast et al.(53) 
37°C, Biacore. Townson et al.(25) 







20°C, ELISA binding assay, EC50. Mi et al.(44) 
37°C, Biacore. Kienast et al.(53) 
37°C, Biacore. Townson et al.(25) 







20°C, ELISA binding assay, EC50. Mi et al.(44) 
37°C, Biacore. Kienast et al.(53) 
37°C, Biacore. Townson et al.(25) 






20°C, ELISA binding assay, EC50. Mi et al.(44) 
37°C, Biacore. Kienast et al.(53) 
37°C, Biacore. Townson et al.(25) 
sENG-Fc 2.7 
0.032 
1.5 37°C, Biacore. Kienast et al.(53) 
20°C, Biacore. Castonguay et al.(21) 
sENG** 9.81  ForeBio Octet Red96, Saito et al. (24) 

























BMP9)	 for	10	minutes	 to	allow	ActA	pre-binding	before	 treatment	with	PBS	or	BMP9	(at	0.3	
ng/ml	 GFD	 concentration)	 for	 an	 additional	 10	 minutes,	 following	 which	 the	 cells	 were	
harvested	for	pSmad1/5	or	pSmad2	immunoblotting.	Since	such	a	short	time	treatment	will	not	






an	 additional	 1	 hour	 before	 qPCR	 analysis	 of	 ID2	 (B)	 or	 an	 additional	 5	 hours	 before	 qPCR	
analysis	 for	BMPR2	 (C)	mRNA	expression,	N=5.	(D)	 Serum-starved	hPAECs	were	pre-treated	
with	PBS	or	BMP4	(at	10x,	25x,	50x,	100x	and	200x	molar	excess	of	BMP9)	for	10	minutes	and	
then	treated	with	PBS	or	BMP9	(at	0.3	ng/ml	GFD	concentration)	for	an	additional	10	minutes,	



































































































































































































































- + + + +
100xBMP4
BMP9 -
Figure 2
